A cascade synergetic strategy induced by photothermal effect based on platelet exosome nanoparticles for tumor therapy

Yang

Front. Bioeng. Biotechnol.

et al. 2022

Liposomes are the earliest and most widely used nanoparticles for targeted drug delivery. Exosomes are nanosized membrane-bound particles and important mediators of intercellular communication. Combining liposomes and exosomes using various membrane fusion methods gives rise to a novel potential drug delivery system called membrane fusion-based hybrid exosomes (MFHE). These novel MFHEs not only exhibit potential advantageous features, such as high drug loading rate and targeted cellular uptake via surface modification, but are also endowed with high biocompatibility and low immunogenicity. Here, we provide an overview of MFHEs’ various preparation methods, characterization strategies, and their applications for disease treatment and scientific research.

“…• Simple • Time-consuming (Piffoux et al, 2018;Kannavou et al, 2021;Ma et al, 2022) • Preservation of EVs and liposomes membrane…”

Section: Peg-incubationmentioning

confidence: 99%

Section: Characterization Of Membrane Fusion-based Hybrid Exosomesmentioning

confidence: 99%

See 1 more Smart Citation

Research progress in membrane fusion-based hybrid exosomes for drug delivery systems

Yang

Front. Bioeng. Biotechnol.

et al. 2022

“…PLTs can be effectively induced to aggregate at the tumor site via interaction with tumor cells through integrin, glycoprotein, and P-selectin on their surface. 50 Therefore, platelets membrane (PLTM)-coated NPs have been developed recently by making the most of the above advantages of platelets. PLTM coatings not only endow superior biocompatibility, low immunogenicity, and long circulation in vivo, 51 but also adhere to the microthrombosis sites of tumor tissues.…”

Section: ■ Cells Membrane Coatingmentioning

confidence: 99%

Surface Membrane Coating as a Versatile Platform for Modifying Antitumor Nanoparticles

Wang

et al. 2022

ACS Materials Lett.

Antitumor nanoparticles now confront several obstacles, including poor biocompatibility and biodegradability, quick removal, and a short cycle time, given the growing interest in surface membrane coating as a versatile platform for altering nanoparticles and overcoming the limitations of current nanodrug delivery methods. This paper reviews the recent progress of cells, synthetic polymers, polyphenols, and polysaccharides membrane coatings with favorable biocompatibility and biodegradability and easy surface modification on the surface of antitumor nanoparticle platforms, which can provide a promising strategy for endowing nanoparticles with specific and expected performance to optimize the efficiency of antitumor. Furthermore, multiple membrane combination strategies and additional biorecognition ligands modification on the membrane surface are supplied in an attempt to tackle the challenges of single membrane coating in a variety of tumor therapeutic applications and ultimately facilitate effective clinical transformation.

“…For example, cell membranes are one kind of common “stealthy” coating, due to their functions, such as intercellular communication, bioantifouling, immune defense, etc. [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ], including, but not limited to, membranes isolated from erythrocyte [ 15 , 16 ], monocyte [ 17 ], macrophage [ 18 , 19 ], neutrophil [ 20 , 21 ], lymphocyte [ 22 , 23 ], and platelet [ 24 , 25 ], which have been reported to mimic cells for DDS protection [ 10 ]. Similarly, the exosomes or extracellular vesicles derived from cells are also important “stealthy” coatings [ 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Drug Delivery Systems with a “Tumor-Triggered” Targeting or Intracellular Drug Release Property Based on DePEGylation

Ren

Liao

et al. 2022

Materials

Coating nanosized anticancer drug delivery systems (DDSs) with poly(ethylene glycol) (PEG), the so-called PEGylation, has been proven an effective method to enhance hydrophilicity, aqueous dispersivity, and stability of DDSs. What is more, as PEG has the lowest level of protein absorption of any known polymer, PEGylation can reduce the clearance of DDSs by the mononuclear phagocyte system (MPS) and prolong their blood circulation time in vivo. However, the “stealthy” characteristic of PEG also diminishes the uptake of DDSs by cancer cells, which may reduce drug utilization. Therefore, dynamic protection strategies have been widely researched in the past years. Coating DDSs with PEG through dynamic covalent or noncovalent bonds that are stable in blood and normal tissues, but can be broken in the tumor microenvironment (TME), can achieve a DePEGylation-based “tumor-triggered” targeting or intracellular drug release, which can effectively improve the utilization of drugs and reduce their side effects. In this review, the stimuli and methods of “tumor-triggered” targeting or intracellular drug release, based on DePEGylation, are summarized. Additionally, the targeting and intracellular controlled release behaviors of the DDSs are briefly introduced.